Filtered By:
Condition: Dementia
Management: WHO
This page shows you your search results in order of date.
Order by Relevance | Date
Total 81 results found since Jan 2013.
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Beware! We are Skating on a Thin Ice: Air Pollution is a Killer
J Assoc Physicians India. 2023 Jul;71(7):11-12.ABSTRACTAir pollution has rapidly emerged as a major environmental hazard in recent times, with potentially catastrophic ramifications for human health.1,2 It has the ability to severely and adversely impact multiple body systems, including the central nervous system (CNS), cardiovascular, dermatological, respiratory, ophthalmologic, and gastrointestinal health. It is a global public health hazard, being responsible for an estimated 6.7 million deaths worldwide in 2016. The World Health Organization (WHO) estimates that between 3.2 to 4.8 million persons succumb yearly because...
Source: Journal of the Association of Physicians of India - July 14, 2023 Category: General Medicine Authors: Man M Mehndiratta Divyani Garg Source Type: research
